Shareholders will be ecstatic, with their stake up 24% over the past week following Surmodics, Inc. 's ( NASDAQ:SRDX...
Surmodics (SRDX) fiscal second-quarter results showcase growth in the medical device segment. The bottom line improves and beats the Zacks Consensus Estimate.
Surmodics Inc reports significant gains in medical device sales and operational achievements, despite challenges in the IVD segment.